Studies Indicate Weight-Loss Drugs May Reduce Breast Cancer Risk by 30%
Recent studies presented at the American Society of Clinical Oncology's annual meeting suggest that weight-loss drugs, specifically GLP-1 medications, may significantly reduce the risk of developing or dying from breast cancer. These drugs, originally used to treat type 2 diabetes and now widely used for weight management, have shown promising results in cancer prevention. One study involving 110,000 women found that those taking GLP-1 medications were 30% less likely to develop breast cancer. Another study indicated that adding these drugs to standard breast cancer treatment reduced the risk of death by 30%. Additionally, research involving patients with various cancers, including breast, lung, bowel, and liver, showed that those on weight-loss drugs were up to 50% less likely to have their disease progress to stage four. 
